Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

119.80
-1.7000-1.40%
Post-market: 119.800.00000.00%19:30 EDT
Volume:503.43K
Turnover:61.16M
Market Cap:9.96B
PE:-37.30
High:125.71
Open:122.87
Low:119.77
Close:121.50
52wk High:130.05
52wk Low:39.84
Shares:83.15M
Float Shares:70.11M
Volume Ratio:0.78
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.60
PE(LYR):-32.47

Loading ...

Kymera Therapeutics Speeds Pipeline Amid Rising Spend

TIPRANKS
·
Aug 21

Kymera Therapeutics on Track for Record High Closing

Dow Jones
·
Aug 17

Kymera Therapeutics (KYMR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 13

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

TIPRANKS
·
Aug 11

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

MT Newswires Live
·
Aug 11

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis

TIPRANKS
·
Aug 06

Kymera Therapeutics, Inc. : Citigroup Raises Target Price to $135 from $120

THOMSON REUTERS
·
Aug 06

Kymera Therapeutics price target raised to $139 from $133 at Barclays

TIPRANKS
·
Aug 06

Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge

Reuters
·
Aug 06

Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment

Reuters
·
Aug 06

Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments

Reuters
·
Aug 06

Editas Medicine Q2 Net Loss Narrows and Beats Estimates

Reuters
·
Aug 06

Kymera Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Kymera Therapeutics Posts Corporate Deck Outlining Push to Develop Oral Targeted Protein Degraders for Immunology

Reuters
·
Aug 05

Kymera Q2 2026 Earnings: Milestone Revenue Narrows Net Loss

TradingKey
·
Aug 05

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Earnings Flash (KYMR) Kymera Therapeutics Posts Q2 Loss $0.62 a Share, vs. FactSet Est of $0.71 Loss

MT Newswires Live
·
Aug 05

Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate

Benzinga Earnings
·
Aug 05